about
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingBRAF Mutation in Hairy Cell LeukemiaIdentification of a Novel Family of BRAF V600E InhibitorsRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.The stable traits of melanoma genetics: an alternate approach to target discoveryGenotyping of cutaneous melanoma.Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.Upcoming strategies for the treatment of metastatic melanoma.Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.New RAF kinase inhibitors in cancer therapy.First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.Double stranded promoter region of BRAF undergoes to structural rearrangement in nearly physiological conditions.Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis.
P2860
Q26774478-B9C5E6DB-D200-404D-B04E-261E11D35961Q27014016-CE55071D-F16F-4C59-AE92-29F1634C4BE4Q27678754-B765B637-972C-413F-8D94-F7387C86BAFDQ30593460-50876EC5-EDC1-4C93-B323-2756E68F28EBQ34248355-E82495DD-F08A-4B7E-B324-351F74A5A068Q34667738-71C2903E-FC99-47BA-BC6F-2B29B1C25825Q36394050-9646439B-71FE-493A-9C9E-30EC0CF8F790Q37373807-C13480E5-F500-4206-8048-55EC152807C0Q37986477-C70A116A-98E1-4ADC-B50D-C11767346265Q38075009-3204973A-7146-4AB9-8BA2-DBE2A1DE0969Q38207082-B3AC9510-B9BC-4C56-9D89-3D738F68F18EQ38405130-1422D037-F96E-4B7F-A7AF-B6BFEEBEF7C9Q42533125-182E6827-E201-4691-8A61-B803EFFA104AQ43138932-8B64C224-441F-4205-89E8-16213601171BQ43697152-9C9B30C5-AA45-47AB-B760-1D05EB262CD1Q44386328-062573B4-A449-444B-B3C6-23C4739086A1Q50957307-18CD01D6-D102-4A73-95BD-FD75591C2018Q53084563-C01BAF11-D0C5-4D7C-8A03-7AAC9D1C6BE7Q54501445-BD017CE9-9890-45B8-BA84-A00CC060754E
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
BRAF as a target for cancer therapy.
@ast
BRAF as a target for cancer therapy.
@en
BRAF as a target for cancer therapy.
@nl
type
label
BRAF as a target for cancer therapy.
@ast
BRAF as a target for cancer therapy.
@en
BRAF as a target for cancer therapy.
@nl
prefLabel
BRAF as a target for cancer therapy.
@ast
BRAF as a target for cancer therapy.
@en
BRAF as a target for cancer therapy.
@nl
P1476
BRAF as a target for cancer therapy.
@en
P2093
Josep Tabernero
Rodrigo Dienstmann
P304
P356
10.2174/187152011795347469
P577
2011-03-01T00:00:00Z